Fig. 5

Construction and evaluation of the predictive signature. (A) Analysis of the overall survival of patients with HCC from TCGA, ICGC, and summary cohorts. (B-C) The distribution of patient’s survival and gene expression in the high-and low-risk groups was analyzed by utilizing the training cohort (TCGA-LIHC) and the validation cohort (ICGC-LIRI-JP). (D) The ROC curve for the training cohort (TCGA-LIHC). (E) The ROC curve for the validation cohort (ICGC-LIRI-JP). Differences were considered statistically significant at P < 0.05